source
- AbbVie inks up to $2.5 billion deal with Disco to pursue bispecific cancer therapeuticsAbbVie announced a collaboration with German biotech Disco Pharmaceuticals that could be worth up to $2.5 billion. The agreement provides a $40 million upfront payment, with the balance linked to…
- Biogen's tau antisense therapy shows 38% slower decline in 2-year Alzheimer extension studyBiogen presented new data from the open‑label extension of its phase 2 Celia trial at the CTAD 2026 conference. The update focused on the tau‑targeting antisense oligonucleotide, diranersen, admini…